SCHEMBL4443124

SCHEMBL4443124

COCCCCCC(=O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.71
L3MBTL1 Q9Y468 2/20 0.71
LMNA P02545 2/20 0.71
MAPT P10636 1/20 0.71
HDAC8 Q9BY41 6/20 0.65
HDAC1 Q13547 6/20 0.65
HDAC3 O15379 2/20 0.65
HDAC4 P56524 2/20 0.65
HDAC7 Q8WUI4 2/20 0.65
HDAC2 Q92769 2/20 0.65
HDAC10 Q969S8 2/20 0.65
HDAC11 Q96DB2 2/20 0.65
HDAC6 Q9UBN7 2/20 0.65
HDAC9 Q9UKV0 2/20 0.65
HDAC5 Q9UQL6 2/20 0.65
ALDH1A1 P00352 1/20 0.55
NPC1 O15118 1/20 0.53
CASP3 P42574 1/20 0.53
RAB9A P51151 1/20 0.53
SENP8 Q96LD8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6591360 0.98 TDP1 (0.68) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL5214695 0.93 TDP1 (0.64) TDP1L3MBTL1LMNAMAPTHDAC8
Hydrochloric Acid SCHEMBL27261595 0.91 TDP1 (0.62) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL12612568 0.87 TDP1 (0.53) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL8599281 0.85 TDP1 (0.77) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL1697056 0.85 MAPT (0.57) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL27516050 0.84 TDP1 (1.00) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL9057671 0.84 TDP1 (1.00) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL8519287 0.84 TDP1 (1.00) TDP1L3MBTL1LMNAMAPTHDAC8
SCHEMBL669665 0.84 GAA (0.56) TDP1L3MBTL1LMNAMAPTHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 US disclosed
US-20090264428-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 US disclosed
EP-0934773-B1 Microcapsule having a specific wall and method for producing the same SEIWA KASEI CO LTD (JP) 2004-02-04 EP disclosed
US-6337089-B1 FOR USE IN COSMETICS SEIWA KASEI COMPANY, LIMITED (JP) 2002-01-08 US disclosed
EP-0934773-A2 Microcapsule having a specific wall and method for producing the same SEIWA KASEI CO., LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 TDP1 1834/4885L3MBTL1 4439/4885LMNA 3150/4885
US-20090264428-A1 Renin Inhibitors REN, ACE, SERPINB1 TDP1 1382/4885L3MBTL1 3320/4885LMNA 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.